Let us see if Hikma keeps up the supply or not---because if they default on the supply then the third-party payors and the pharmacies have a serious problem because patients therapeutic benefit is at stake and that is litigable. If the gen V is substituted but not fulfilled due to lack of supply, and the patients go with weeks of no supply of the Tier1 ...very rapidly Vascepa will be back as acceptable. Patients accept a lot for savings but physicians might not.. HK
Market Data 
Markets 
AI
